Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cranberries & UTIs

This article was originally published in The Tan Sheet

Executive Summary

NCCAM calls for supplies of cranberry juice cocktail, concentrate and encapsulated powders, with matching placebos, in Request For Information posted on center's Web site. Collected cranberry products will be used in "NIH-supported research, specifically (but not exclusively) for basic and clinical research on the role of cranberry (Vaccinium macrocarpon) in the prevention and treatment of urinary tract infections." Request marks an initial step in cranberry initiative approved at NCCAM's advisory council meeting Aug. 27 (1"The Tan Sheet" Sept. 3, p. 4)

You may also be interested in...



NCCAM Slowing Research Pace, Turning To Program Announcements

The National Center for Complementary & Alternative Medicine will issue proportionately more program announcements (PAs) in the coming year than requests for applications (RFAs), hedging against a possible upsurge of out-year costs for funded grants.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel